Veracyte (VCYT) Competitors $43.05 -0.55 (-1.26%) Closing price 04:00 PM EasternExtended Trading$43.06 +0.02 (+0.03%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends VCYT vs. HIMS, OPCH, GH, RDNT, SHC, BTSG, LFST, CON, PRVA, and SGRYShould you be buying Veracyte stock or one of its competitors? The main competitors of Veracyte include Hims & Hers Health (HIMS), Option Care Health (OPCH), Guardant Health (GH), RadNet (RDNT), Sotera Health (SHC), BrightSpring Health Services (BTSG), LifeStance Health Group (LFST), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), and Surgery Partners (SGRY). These companies are all part of the "healthcare" industry. Veracyte vs. Hims & Hers Health Option Care Health Guardant Health RadNet Sotera Health BrightSpring Health Services LifeStance Health Group Concentra Group Holdings Parent Privia Health Group Surgery Partners Veracyte (NASDAQ:VCYT) and Hims & Hers Health (NYSE:HIMS) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability. Is VCYT or HIMS more profitable? Hims & Hers Health has a net margin of 8.19% compared to Veracyte's net margin of -2.18%. Hims & Hers Health's return on equity of 10.97% beat Veracyte's return on equity.Company Net Margins Return on Equity Return on Assets Veracyte-2.18% 3.02% 2.80% Hims & Hers Health 8.19%10.97%8.29% Do insiders and institutionals have more ownership in VCYT or HIMS? 63.5% of Hims & Hers Health shares are held by institutional investors. 1.3% of Veracyte shares are held by insiders. Comparatively, 17.7% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in VCYT or HIMS? Veracyte received 401 more outperform votes than Hims & Hers Health when rated by MarketBeat users. Likewise, 73.06% of users gave Veracyte an outperform vote while only 39.05% of users gave Hims & Hers Health an outperform vote. CompanyUnderperformOutperformVeracyteOutperform Votes44273.06% Underperform Votes16326.94% Hims & Hers HealthOutperform Votes4139.05% Underperform Votes6460.95% Which has preferable earnings & valuation, VCYT or HIMS? Hims & Hers Health has higher revenue and earnings than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVeracyte$361.05M9.24-$74.40M-$0.15-287.00Hims & Hers Health$872M7.43-$23.55M$0.4467.44 Does the media prefer VCYT or HIMS? In the previous week, Hims & Hers Health had 20 more articles in the media than Veracyte. MarketBeat recorded 25 mentions for Hims & Hers Health and 5 mentions for Veracyte. Veracyte's average media sentiment score of 0.89 beat Hims & Hers Health's score of 0.66 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hims & Hers Health 14 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer VCYT or HIMS? Veracyte presently has a consensus price target of $41.13, suggesting a potential downside of 4.47%. Hims & Hers Health has a consensus price target of $25.13, suggesting a potential downside of 15.30%. Given Veracyte's stronger consensus rating and higher probable upside, research analysts plainly believe Veracyte is more favorable than Hims & Hers Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veracyte 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67Hims & Hers Health 2 Sell rating(s) 7 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.35 Which has more volatility & risk, VCYT or HIMS? Veracyte has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500. SummaryHims & Hers Health beats Veracyte on 11 of the 18 factors compared between the two stocks. Get Veracyte News Delivered to You Automatically Sign up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCYT vs. The Competition Export to ExcelMetricVeracyteMedical laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.14B$3.04B$5.36B$9.13BDividend YieldN/A16.58%5.37%4.00%P/E RatioN/A12.0674.7215.64Price / Sales9.36204.431,287.0785.06Price / Cash437.23393.5036.3232.99Price / Book3.055.244.974.69Net Income-$74.40M-$33.85M$117.89M$224.57M7 Day Performance4.51%4.49%1.74%1.69%1 Month Performance6.63%1.06%3.69%5.34%1 Year Performance65.34%17.87%25.82%21.47% Veracyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCYTVeracyte3.9523 of 5 stars$43.05-1.3%$41.13-4.5%+70.8%$3.34B$361.05M-287.00790News CoverageHIMSHims & Hers Health3.539 of 5 stars$27.80-0.5%$25.13-9.6%+257.0%$6.07B$872M63.191,046Insider TradeOPCHOption Care Health4.7608 of 5 stars$29.16-0.5%$29.86+2.4%-8.0%$4.96B$4.30B24.507,802Positive NewsGHGuardant Health3.4099 of 5 stars$36.66-1.7%$40.60+10.7%+94.4%$4.53B$563.95M-8.651,779Analyst ForecastNews CoverageRDNTRadNet3.5292 of 5 stars$59.86-1.7%$79.75+33.2%+59.3%$4.43B$1.62B-855.0210,288Analyst ForecastNews CoverageSHCSotera Health2.7372 of 5 stars$12.98+2.3%$16.08+23.9%-11.1%$3.68B$1.05B51.923,000BTSGBrightSpring Health Services2.186 of 5 stars$18.55+0.4%$18.65+0.6%N/A$3.23B$8.83B-71.3535,000News CoverageLFSTLifeStance Health Group1.1646 of 5 stars$7.99+0.1%$8.70+8.9%+17.3%$3.06B$1.06B-30.739,325Positive NewsCONConcentra Group Holdings ParentN/A$21.17+0.7%$28.50+34.6%N/A$2.70B$1.88B0.0011,000Lockup ExpirationPositive NewsGap DownPRVAPrivia Health Group2.6215 of 5 stars$22.24+1.8%$24.88+11.9%+9.1%$2.67B$1.66B222.421,102SGRYSurgery Partners1.7847 of 5 stars$20.19+1.0%$36.56+81.1%-36.2%$2.57B$2.99B-42.0613,500 Related Companies and Tools Related Companies Hims & Hers Health Competitors Option Care Health Competitors Guardant Health Competitors RadNet Competitors Sotera Health Competitors BrightSpring Health Services Competitors LifeStance Health Group Competitors Concentra Group Holdings Parent Competitors Privia Health Group Competitors Surgery Partners Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VCYT) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredKamala’s final humiliation Now, for the first time, I’m going to share these ten investments publicly – the same ones I’ve discussed behi...Porter & Company | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veracyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.